

Reviewer #1 (Comments to the author(Required))

This is an interesting review about ANXA2 in cancer biology. To support readers' understanding of ANXA2, some modifications are necessary.

1. The first reported paper about ANXA2 was missing. The paper should be clearly referred.

Response: We appreciate the point raised by the reviewer. The citation of the first reported paper about ANXA2 has been added to the article. (Page 6, Line 1-3; Ref No.30)

2. The basic information about ANXA2 should be introduced in the text; coding gene, chromosome, protein size, and biological function in normal cell.

Response: Thanks for the note! The specific information about coding gene, chromosome, protein size, and biological function of ANXA2 has been added to the text of INTRODUCTION. (Page 6, Line 3-22; Ref No.31- 36)

3. In the present review, many papers were introduced that ANXA2 was closely associated with several kinds of cancers, not only HCC. However, it was not enough to support the role of ANXA2 in hepatocarcinogenesis through involvement of immune microenvironment. Title was not matched with the content.

Response: We totally agree with the reviewer's comments. Therefore, we revised the title as "Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment", further added the corresponding content about "Upregulation of ANXA2" (Page 7, Line 16-20), "ROLE OF ANXA2 IN THE CHAOTIC IMMUNE MICROENVIRONMENT" (Page 10, Line 17-21) and "ROLE OF ANXA2 IN THE CHAOTIC IMMUNE MICROENVIRONMENT" (Page 11, Line 2-9 and Page 11, Line 30 to Page 12, Line 4) in the article, and updated thereferences, respectively. (Ref No.51,90,97 and 103)

4. Sorafenib has not been only systemic therapeutic agent for HCC. Now, Lenvatinib has been added the first line for systematic therapeutic agent. Author should revise the sentence.

Response: Thanks for pointing this out! We have made this correction to make the sentence consistent with the objective facts. (Page 5, Line 15-19)

5. Minor; Misspelling.

Response: Thanks for the note! Misspellings have been corrected.

6. 'Nonalcoholic fatty liver disease' and 'non-alcoholic fatty liver disease' were same disease. The same words should be used.

Response: Thanks for the suggestion. 'Nonalcoholic fatty liver disease' has been replaced by 'nonalcoholic fatty liver disease'. (Page 8, Line 1)

7. Line 22, 22, page 6. Line 5-6, page 9; Two sentence was the same meaning. One of them should be removed.

Response: Thanks for the suggestion. One of the two sentences has been deleted.

8. The abbreviations for 'Tregs' and 'DCs' were necessary in line 11, and line 12, page 10 respectively.

Response: Thanks for the suggestion. The abbreviations for 'Tregs' and 'DCs' have been added to the article. (Page 4, Line 9-11)